| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Parasitology and Immunology, University of Tokushima School of Medicine, Tokushima, Japan;
Chemistry Laboratory, Taiho Pharmaceutical Co., Hanno, Japan;
All Children’s Hospital, University of South Florida, St. Petersburg, FL; and
§
Institute for Health Sciences, Tokushima Bunri University, Tokushima, Japan
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
in contrast to untreated and infected mice
that produced IgG1 and IgE and generated IL-4. CA074 interfered with
the digestion of L. major Ags with lysosomal enzymes in
vivo as well as in vitro. However, this inhibitor did not show any
direct influence on the growth of L. major and the
functions of T cells stimulated with anti-CD3 Ab. These findings
indicate that cathepsin B inhibitor could switch CD4+ T
cell differentiation from Th2 to Th1, suggesting that the alteration in
Ag processing modulates the polarity of Th
differentiation. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Mice resistant to infection with Leishmania major, such as
the DBA/2, C3H, CBA, or C57BL/6 strains, preferentially develop
CD4+ Th1 cells specific for L. major Ags (9, 10). Th1 cells generate IL-2 and IFN- and support the production of
Ag-specific IgG2a-type Ab (11, 12). On the other hand, susceptible
BALB/c mice exclusively develop Th2 CD4+ T cells, which
generate IL-4 and IL-5 and support production of specific Abs of the
IgE and IgG1 classes. Furthermore, it is well established that Th1 and
Th2 cells regulate each other in mice infected with L. major
(13, 14). However, the mechanisms involved in the preferential
development of Ag-specific Th1 or Th2 type CD4+ T cells
remain to be defined.
In the present study, we have examined the effect of treatment with CA074 on murine leishmaniasis in susceptible BALB/c mice, in an effort to elucidate the participation of lysosomal cysteine proteases in the functional differentiation of Th1 and Th2 cells. We show here that modulation in Ag processing by a cathepsin B inhibitor suppresses the functional differentiation of Th2 type CD4+ T cells and in turn augments Th1-type immune responses. These findings indicate that the cathepsin B inhibitor modulates the polarity of Th differentiation by the alteration in Ag processing.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Female BALB/c CrSlc (BALB/c) and DBA/2 CrSlc (DBA/2) mice were purchased from Japan Shizuoka Laboratory Animal Center (Hamamatsu, Japan), and CB-17 scid/scid (SCID) mice were obtained from the Central Institute for Experimental Animals (Kawasaki, Japan). The animals were 8 to 10 wk of age at the beginning of the experiment.
Parasites
Cultures of L. major (MHOM/SU/73/5ASKH) were provided by Dr. Furuya, Kochi Medical College, Japan. The parasites were propagated in Schneider medium containing 20% FBS (Life Technologies, Grand Island, NY). Promastigotes were harvested from stationary phase cultures by centrifugation and washed at least three times in PBS. Parasites were passed at intervals in BALB/c female mice to ensure that virulence was maintained.
Ags and reagents
Ags were prepared using stationary phase promastigotes of L. major. Soluble leishmanial Ag (SLA)3 was prepared as described (15) and the protein concentration determined using the bicinchoninic acid (BCA) protein assay reagent (Pierce, Rockford, IL). Cathepsin B inhibitor, CA074, was synthesized in our laboratory and the specificities confirmed as described (6, 7). CA074 dissolved in PBS was administered at doses of 0.5 mg/mouse/day. The inhibitor was given 2 h before inoculation of the parasites, and administration of the inhibitor was continued every 12 h for the indicated periods. For the measurement of mouse IL-5, mAb to mouse IL-5 (Genzyme, Cambridge, MA) and biotin-conjugated mAb (TRFK4) against IL-5 (PharMingen, San Diego, CA) were used as detecting and coating Abs, respectively. Anti-mouse CD3 Ab (2C11) was a gift from Dr. Nomoto (Kyushu University, Fukuoka, Japan). Recombinant murine IL-2 was a gift from Shionogi (Osaka, Japan), and recombinant murine IL-4 and IL-12 were purchased from Intergen (Purchase, NY) and Genzyme, respectively.
Measurement of enzyme activity
Liver, spleen, lymph nodes (LN), and peritoneal macrophages were used to assay for cathepsin B activity. To obtain macrophages, BALB/c mice were injected i.p. with 2 ml of 4.05% (w/v) thioglycollate medium (Wako, Osaka, Japan). Four days after injection, peritoneal cells were collected and plated on plastic plate. After adherence for 1 h, monolayer cells were used as the peritoneal macrophages. Lysosomes were isolated for the assay by gently homogenizing samples using a Teflon pestle in 0.25 M cold sucrose. The suspension was centrifuged at 3,500 x g for 10 min at 4°C. The supernatant was centrifuged at 25,000 x g for 20 min at 4°C. The resulting pellet was resuspended with 50 mM acetate buffer (pH 5.0). The suspension fluid was frozen and thawed three times to disrupt lysosomal membranes. After three cycles of freezing and thawing, the fluid was centrifuged and the supernatant was used as a mitochondria and lysosome fraction (ML fraction). Cathepsin B activity in ML fraction was assayed with Z-Arg-Arg-methyl coumarylamide (Peptide Institute, Osaka, Japan) as substrate at pH 5.0 by the method of Barrett and Kirschke (16). The reaction was initiated by addition of substrate (10 µM final concentration) after preincubation with the test compound for 3 min at 37°C. The fluorescence of the liberated 7-amino-4-methylcoumarin was measured in a fluorescence spectrophotometer (Hitachi, Tokyo, Japan). Emission at 460 nm was measured with excitation at 370 nm.
Establishment and assessment of infection
Mice were inoculated with L. major s.c. in the footpads. For primary infection, 5 x 106 promastigotes were injected into the left hind footpad, and for rechallenge, the same number of promastigotes were injected into the right hind footpad 60 days after the first infection. The progression of infection was assessed by monitoring lesion development by measuring the footpad thickness with a vernier caliper.
In vitro L. major proliferation assay
Promastigotes of L. major were cultured in Schneider medium containing 20% FBS with or without CA074 for 72 h at 25°C. The proliferation of L. major was evaluated by counting the parasites every 24 h.
Measurement of serum Ig by ELISA
SLA was covalently coated onto 96-well CovaLink NH plates (Nunc, Roskilde, Denmark). After blocking with 0.1% BSA in PBS (blocking buffer), the SLA was incubated with serum samples serially diluted in the blocking buffer for 6 h at 4°C. The results were developed using alkaline phosphatase-conjugated murine isotype-specific mAb, anti-mouse IgG (Sigma, St. Louis, MO), anti-mouse IgG1 or IgG2a (Organon Teknika, West Chester, PA), or anti-mouse IgE (Southern Biotechnology, Birmingham, AL) followed by p-nitrophenyl phosphate (Sigma). After terminating the reaction with 3N, NaOH, OD at 415 nm was determined on a microplate reader (Corona Electric, Katsuta, Japan).
Immunoblotting
SLA was separated by SDS-PAGE, then the gel was electroblotted onto a polyvinylidine difluoride membrane (Millipore, Bedford, MA). Sera from L. major-infected BALB/c mice or L. major-infected BALB/c mice treated with CA074 were used as the first Abs. Peroxidase-conjugated goat anti-mouse IgG (Zymed, San Francisco, CA) was the second Ab. Binding Abs were detected by means of the enhanced chemiluminescence method (Amersham, Buckinghamshire, U.K.), based on a combination of enhanced chemiluminescence detection. Fluorescence emitted from luminol in the presence of peroxidase could be detected by autoradiography film (Fuji Film, Tokyo, Japan).
Measurement of cytokine production
Cells from popliteal LNs draining the footpad lesions were
cultured with SLA (20 µg/ml) for 72 h. IFN- and IL-4
production in the supernatants was measured using ELISA EM-IFNG and
EM-IL4 (Endogen, Cambridge, MA) kits.
T cell stimulation
Splenocytes (2 x 105/well) from BALB/c mice were stimulated with anti-CD3 Ab (2C11) or Con A (Sigma) for 72 h. For the proliferation assay, [3H]TdR (1 µCi/well) was added to each well 6 h before harvesting. The cytokines in the supernatants were measured by ELISA.
T cell purification
T cells of splenocytes from naive female BALB/c mice were purified using a nylon fiber column (Wako). This procedure was performed twice, and the purity of T cells was >95% as judged by flow cytometry analysis.
Digestion of SLA with proteases in ML fraction
SLA was digested at pH5.0, 37°C, for 2 h with lysosomal enzymes in an ML fraction of splenocytes from naive or CA074-treated BALB/c mice. After digestion, reaction samples were separated by SDS-PAGE. The digested products of SLA were detected by immunoblotting method using Abs in serum from L. major-infected BALB/c mice.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In this study, we first investigated the inhibitory effect of
CA074 on cathepsin B activity in vivo. After administration of CA074,
the kinetics of cathepsin B activity was examined. As shown in Figure 1
A, the activity in liver
cells was reduced to 
20 to 25% at 2 h after administration of
0.25 mg of CA074 per mouse, with 50% inhibition at 12 h. Next, we
used the thioglycollate-induced peritoneal adherent cells to evaluate
in vivo inhibition of cathepsin B activity. Two hours before
collection, 0.25 mg of CA074 was injected into the peritoneal cavity.
In macrophages, 75 to 80% inhibition of cathepsin B activity was
observed (Fig. 1B). These findings suggested that the dose
of cathepsin B inhibitor, CA074, used in this study was sufficient to
inactivate the cathepsin B activity.
|
We examined the effect of CA074 on murine leishmaniasis. In
comparison with PBS-treated BALB/c mice that showed progressive footpad
swelling, BALB/c mice treated with CA074 (0.5 mg/day (0.25 mg/12 h))
became resistant to L. major infection (Fig. 2A). Next, we examined whether
this inhibitor modulated the resistance of DBA/2 mice. DBA/2 strain is
compatible with H-2 in BALB/c mice but resistant to L.
major. As shown in Figure 2B, CA074 did not influence
the disease progression in resistant DBA/2 mice, suggesting that
cathepsin B inhibitor did not suppress the genetically strong Th1
response in this strain. E64d, a more broad inhibitor for cysteine
proteases, induced a similar inhibition of L. major induced
footpad swelling like CA074 (data not shown).
|
To exclude the possibility that CA074 exerts a direct cytotoxic
effect on L. major, we examined the influence of CA074 on
the in vitro proliferation of L. major promastigotes. As
shown in Figure 3A, L.
major proliferated comparably regardless of presence or absence of
CA074.
|
B, no
difference in lesion footpad thickness was observed between PBS- and
CA074-treated SCID mice. Moreover, the speed of disease progression and
pattern of lesions were similar between protease inhibitor-treated or
untreated nude mice (data not shown). Thus, cathepsin B-specific
inhibitor did not directly influence the infectivity of L.
major, suggesting that the resistance in CA074-treated BALB/c mice
was acquired through an immunologic mechanism lacking in the
immunodeficient SCID or nude mice. Reinfection with L. major in BALB/c mice treated with CA074
We then investigated the mechanisms of resistance in BALB/c mice
treated with cathepsin B-specific inhibitor. Infected BALB/c mice
treated with CA074 or PBS were later reinfected into the contralateral
footpad 60 days after the primary infection. Swelling in the reinfected
footpad prominently progressed in naive and PBS-treated BALB/c mice,
whereas CA074-treated BALB/c mice were completely resistant whether or
not additional CA074 had been given (Fig. 4). Thus, infected BALB/c mice treated
with CA074 acquired protective immunity.
|
We examined the proportion of each subclass of L.
major-specific Ab in the serum to evaluate the immunologic status
of infected mice (Fig. 5A). No
difference in the amount of L. major-specific IgG was
observed between PBS- and CA074-treated BALB/c mice. The amount of
IgG2a was slightly higher in CA074-treated mice than in PBS-treated
mice. On the other hand, the production of IgG1 and IgE Abs promoted by
Th2 cells was markedly suppressed in the CA074-treated mice as compared
with that in PBS-treated mice, indicating possible inhibition of Th2
function by the cathepsin B-specific inhibitor.
|
B). In contrast to sera
from PBS-treated BALB/c mice, those from CA074-treated mice strongly
recognized 20- and 50-kDa Ags in SLA but did not bind 30-kDa Ags,
suggesting that the Abs specific for 20- and 50-kDa Ags were increased,
but those specific for 30-kDa Ags were decreased in serum from
CA074-treated mice. That is, the production of Abs specific for
L. major Ags may be changed by treatment with CA074 in
isotype, and Abs of mice treated with CA074 may recognize different
molecules in L. major Ags from those of PBS-treated mice. The functional phenotype of T cells in CA074-treated BALB/c mice
We examined the functional phenotype of CD4+ T cells
in BALB/c mice that acquired resistance against L. major
infection after treatment with CA074. Cells from LNs draining the
footpad lesions of infected mice were stimulated with SLA, then IL-4 or
IFN-, indicating Th2 or Th1 responses, respectively, in the culture
supernatants were assessed by ELISA (Fig. 6). High levels of IL-4, but not IFN-,
were produced in PBS-treated mice. In contrast, treatment with CA074
increased IFN- production and decreased production of IL-4. Thus,
the pattern of cytokines produced in PBS-treated mice was of the Th2
type and of Th1 type in CA074-treated mice. These results suggest that
Th2 function had been suppressed in BALB/c mice by treatment with CA074
so that Th1 function could be sufficiently activated to resolve
infection with L. major. Thus, inactivation of cathepsin B
appears to inhibit the development of Th2-type immune responses that
ordinarily develop in BALB/c mice infected with L. major
and, as a result, favors the development of Th1 cells.
|
We then examined the cathepsin B activity in peripheral lymphoid
organs. In popliteal LNs draining the footpad lesions of infected mice,
cathepsin B activity remained 70 to 80% 2 h after i.p.
treatment with CA074 (Fig. 7). Although
cathepsin B activity was inhibited 70 to 80% in liver and APCs
(Fig. 1), the activity in peripheral LNs was inhibited only 20 to
30% via i.p. administration. However, local treatment with CA074 could
inhibit the activity in draining LNs (data not shown), suggesting that
lymphoid organs are not resistant to this compound. At present, we do
not know why peritoneal treatment did not inhibit the activity in LNs
as well as in liver. These results suggested that only an 20 to 30%
reduction of cathepsin B activity is sufficient to induce the
inhibition of the development of Th2-type immune responses and the
promotion of the development of Th1 cells.
|
Naive splenocytes from BALB/c mice were stimulated with Con
A or plate-fixed anti-CD3 Ab. To evaluate the influence of
CA074, we added this inhibitor to the culture. As shown in Figure 8, CA074 did not affect either the
proliferative response or the production of IFN- or IL-4
(Fig. 8, B and C). Next, we examined the effect
of CA074 on Th differentiation initiated with cytokines such as IL-4 or
IL-12. The combination of some cytokines induces the Th1 or Th2 from
naive T cells (17, 18, 19). When naive T cells were stimulated with IL-2
plus IL-4, they differentiated into IL-4-producing cells; however, the
addition of CA074 in this culture did not affect the production of
IL-4, IL-5, or IFN- (Fig. 9A). It is well known that
combined treatment with IL-2 and IL-12 causes naive T cells to
differentiate into IFN--producing cells. The presence of CA074 in
the culture did not change the production pattern of cytokines (Fig. 9B). Thus, the cathepsin B inhibitor did not directly
influence the T cell responses, and the switch from Th2 to Th1 is not
due to the direct effect on T cell responses.
|
|
We supposed that the shift of Th differentiation from Th2 to Th1
in CA074-treated mice was induced by the modulation in Ag processing
owing to the inhibition of lysosomal cathepsin B activity. Therefore,
we first examined in vitro the change in the digestion of SLA with
splenic lysosomal fraction by adding CA074 to the reaction mixture. As
shown in Figure 10A, the
amount of 28-kDa Ag in SLA (indicated with a closed triangle) was
decreased according to the digestion with lysosomal enzymes, whereas
16-kDa protein (indicated with a open triangle) was increased compared
with the reaction mixture without lysosomal fraction. However, when
CA074 was added to the reaction mixture, 28-kDa Ag was not decreased,
but rather, 16-kDa-digested product was decreased. Next, we compared
the digestion pattern of SLA by lysosomal enzymes prepared from splenic
macrophages of uninfected BALB/c mice treated with or without CA074
(Fig. 10B). Similar to the in vitro effect of CA074, the
16-kDa-digested product almost disappeared in the reaction mixture with
the lysosomal fraction from CA074-treated mice. Thus, CA074 appears to
influence Ag processing in vivo as well as in vitro.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Many factors, especially cytokines, regulate the functional
differentiation of CD4+ T cells. Alteration in the cytokine
environment changes the Th1/Th2 balance as has been shown by other
studies with murine leishmaniasis (9, 10). For example, IFN- and
IL-4 generated by Th1 and Th2 cells, respectively, reciprocally
counterregulate the differentiation of Th1 and Th2 cells from their
precursor cells (13, 14). That is, IFN- enhances the development of
Th1 but inhibits development of Th2 cells (20, 21), and the in vivo
administration of monoclonal anti-IFN- Abs attenuates Th1
responses (22). On the other hand, IL-4 promotes the opposite effect to
IFN- in Leishmania-infected mice (23). Thus, CA074 may
have a potential to induce the production of IFN- or IL-4 by T cells
through a direct effect to them. This possibility, however, was
negated (Fig. 8). Moreover, CA074 did not exert the direct influence on
Th differentiation that was induced with cytokines such as IL-4 or
IL-12 (Fig. 9).
IL-12 (24, 25, 26) and IFN--inducing factor (IGIF or IL-18) (27)
secreted by macrophages play key roles in the induction of Th1
responses, and NK1.1+ T cells promote the development of
Th2 cells by secreting IL-4 (28, 29). However, CA074 exerts neither an
in vivo inhibitory effect on IL-4 production by NK1.1+ T
cells nor an in vitro promoting effect on the production of IL-12 and
IGIF by macrophages (data not shown). CD80 and CD86 expressed on
activated APCs reportedly transfer signals that promote the
differentiation of CD4+ T cells into Th1 and Th2 T cells,
respectively (30, 31, 32). Accordingly, we investigated whether CA074
directly influences the expression of these molecules, employing in
vitro experiments that used LPS-activated B cells. However, this
possibility was also excluded (data not shown).
Before CD4+ T cell activation, Ags must be processed with lysosomal proteases after endocytosis. Although lysosomal proteases responsible for Ag processing have not yet been well defined, cathepsin B (3, 4, 5), D (4, 33), and E (34) have been shown to play major roles. Thus far, there is no report suggesting that some proteases preferentially create motifs that select either Th1- or Th2-type Ag-specific CD4+ T cells. As shown here, the Th2 response was suppressed in BALB/c mice infected with L. major and treated with CA074, while the Th1 response, essential to protective immunity against this infection, became dominant. A similar effect with CA074 was observed when so-called IgE-inducible Ags such as OVA (8) or Nippostrongylus brasiliensis (data not shown) were used as Ags. Thus, inactivation of cathepsin B with a specific inhibitor is expected to influence immune responses, especially the functional differentiation of CD4+ T cells. At present, the detailed molecular mechanisms of how the inhibitor of cathepsin B induces the switching of polarity from Th2 type to Th1 type have not been clarified, although this inhibitor was confirmed to modulate Ag processing with lysosomal enzymes in vivo as well as in vitro.
It is important to elucidate in molecular detail the switching mechanisms responsible for T cell development from Th2- to Th1-type immune responses in mice treated with cathepsin B inhibitors. This approach may allow an understanding of the mechanism(s) underlying CD4+ T cell differentiation and the immune deviation toward IgE production that is often seen clinically.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Kunisuke Himeno, Department of Parasitology and Immunology, School of Medicine, The University of Tokushima, Kuramoto-cho 3, Tokushima 770-8503, Japan. E-mail address:
3 Abbreviations used in this paper: SLA, soluble leishmanial Ag; LN, lymph node; ML fraction, mitochondria and lysosome fraction; IGIF, IFN--inducing factor.
Received for publication June 16, 1997. Accepted for publication April 23, 1998.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J. Immunol. 147:3149.[Abstract]
production and diminishes interleukin 4 inhibition of such priming. Pro. Natl. Acad. Sci. USA 90:10188. direct the development of distinct subunits of helper T cells. Fed. Proc. 4:2020.
production is IFN--dependent. Int. Immunol. 5:1119. antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J. Immunol. 143:266.[Abstract]
-independent mechanism. J. Exp. Med. 171:115. production by T cells. Nature 378:88.[Medline]
This article has been cited by other articles:
|
|
 |
|
  K. Bryson, S. Besteiro, H. A. McGachy, G. H. Coombs, J. C. Mottram, and J. Alexander Overexpression of the Natural Inhibitor of Cysteine Peptidases in Leishmania mexicana Leads to Reduced Virulence and a Th1 Response Infect. Immun., July 1, 2009; 77(7): 2971 - 2978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Elkaim, S. Werner, L. Kocgozlu, and H. Tenenbaum P. gingivalis Regulates the Expression of Cathepsin B and Cystatin C Journal of Dental Research, October 1, 2008; 87(10): 932 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Burster, T. Giffon, M. E. Dahl, P. Bjorck, M. Bogyo, E. Weber, K. Mahmood, D. B. Lewis, and E. D. Mellins Influenza A virus elevates active cathepsin B in primary murine DC Int. Immunol., May 1, 2007; 19(5): 645 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ponte-Sucre, R. Vicik, M. Schultheis, T. Schirmeister, and H. Moll Aziridine-2,3-dicarboxylates, peptidomimetic cysteine protease inhibitors with antileishmanial activity. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2439 - 2447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Schierack, R. Lucius, B. Sonnenburg, K. Schilling, and S. Hartmann Parasite-Specific Immunomodulatory Functions of Filarial Cystatin Infect. Immun., May 1, 2003; 71(5): 2422 - 2429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Gantt, S. Schultz-Cherry, N. Rodriguez, S. M. B. Jeronimo, E. T. Nascimento, T. L. Goldman, T. J. Recker, M. A. Miller, and M. E. Wilson Activation of TGF-{beta} by Leishmania chagasi: Importance for Parasite Survival in Macrophages J. Immunol., March 1, 2003; 170(5): 2613 - 2620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. J. Pollock, K. S. McNeil, J. C. Mottram, R. E. Lyons, J. M. Brewer, P. Scott, G. H. Coombs, and J. Alexander The Leishmania mexicana Cysteine Protease, CPB2.8, Induces Potent Th2 Responses J. Immunol., February 15, 2003; 170(4): 1746 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Somanna, V. Mundodi, and L. Gedamu Functional Analysis of Cathepsin B-like Cysteine Proteases from Leishmania donovani Complex. EVIDENCE FOR THE ACTIVATION OF LATENT TRANSFORMING GROWTH FACTOR beta J. Biol. Chem., July 5, 2002; 277(28): 25305 - 25312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.P. Dickinson CYSTEINE PEPTIDASES OF MAMMALS: THEIR BIOLOGICAL ROLES AND POTENTIAL EFFECTS IN THE ORAL CAVITY AND OTHER TISSUES IN HEALTH AND DISEASE Critical Reviews in Oral Biology & Medicine, May 1, 2002; 13(3): 238 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Dainichi, Y. Maekawa, K. Ishii, T. Zhang, B. F. Nashed, T. Sakai, M. Takashima, and K. Himeno Nippocystatin, a Cysteine Protease Inhibitor from Nippostrongylus brasiliensis, Inhibits Antigen Processing and Modulates Antigen-Specific Immune Response Infect. Immun., December 1, 2001; 69(12): 7380 - 7386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Zhang, Y. Maekawa, T. Sakai, Y. Nakano, K. Ishii, H. Hisaeda, T. Dainichi, T. Asao, N. Katunuma, and K. Himeno Treatment with cathepsin L inhibitor potentiates Th2-type immune response in Leishmania major-infected BALB/c mice Int. Immunol., August 1, 2001; 13(8): 975 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Okano, A. R. Satoskar, K. Nishizaki, and D. A. Harn Jr. Lacto-N-fucopentaose III Found on Schitosoma mansoni Egg Antigens Functions as Adjuvant for Proteins by Inducing Th2-Type Response J. Immunol., July 1, 2001; 167(1): 442 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Szpaderska and A. Frankfater An Intracellular Form of Cathepsin B Contributes to Invasiveness in Cancer Cancer Res., April 1, 2001; 61(8): 3493 - 3500. [Abstract] [Full Text]
|
|
|
|
|
|
L. Das, N. Datta, S. Bandyopadhyay, and P. K. Das Successful Therapy of Lethal Murine Visceral Leishmaniasis with Cystatin Involves Up-Regulation of Nitric Oxide and a Favorable T Cell Response J. Immunol., March 15, 2001; 166(6): 4020 - 4028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.-P. Shi, R. A.R. Bryant, R. Riese, S. Verhelst, C. Driessen, Z. Li, D. Bromme, H. L. Ploegh, and H. A. Chapman Role for Cathepsin F in Invariant Chain Processing and Major Histocompatibility Complex Class II Peptide Loading by Macrophages J. Exp. Med., April 3, 2000; 191(7): 1177 - 1186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Selzer, S. Pingel, I. Hsieh, B. Ugele, V. J. Chan, J. C. Engel, M. Bogyo, D. G. Russell, J. A. Sakanari, and J. H. McKerrow Cysteine protease inhibitors as chemotherapy: Lessons from a parasite target PNAS, September 28, 1999; 96(20): 11015 - 11022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Reijonen, J. F. Elliott, P. van Endert, and G. Nepom Differential Presentation of Glutamic Acid Decarboxylase 65 (GAD65) T Cell Epitopes Among HLA-DRB1*0401-Positive Individuals J. Immunol., August 1, 1999; 163(3): 1674 - 1681. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
